IDH1 and central nervous system cancer: Reportedly, among the three isoforms of IDH in humans, frequent somatic mutations of IDH1 have recently been found in certain cancers including nearly 80% in grade II-III gliomas, appropriate 45% in secondary glioblastoma multiforme (GBM), and 33%-50% in adult primitive neuroectodermal tumor [3, 4].